KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

NCT06411691 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer
Pancreatic Cancer

Interventions

DRUG: KRAS Vaccine with Poly-ICLC adjuvant
DRUG: Balstilimab
DRUG: Botensilimab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]